^
BIOMARKER:

MYC amplification

i
Other names: MYC, bHLHe39, c-Myc, MYCC, V-myc avian myelocytomatosis viral oncogene homolog
Entrez ID:
MYC amplification
NSCLC
gefitinib
Sensitive: B - Late Trials
MYC amplification
Small Cell Lung Cancer
AZD1775
Sensitive: C2 – Inclusion Criteria
MYC amplification
Esophageal Cancer
ibrutinib
Sensitive: C2 – Inclusion Criteria
MYC amplification
Melanoma
Immunotherapy
Sensitive: C3 – Early Trials
MYC amplification
Ovarian Cancer
durvalumab
Resistant: C3 – Early Trials
MYC amplification
Triple Negative Breast Cancer
talazoparib
Resistant: C3 – Early Trials
MYC amplification
NSCLC
osimertinib
Resistant: C3 – Early Trials
MYC amplification
Ovarian Cancer
bevacizumab
Sensitive: C3 – Early Trials
MYC amplification
Small Cell Lung Cancer
talazoparib + GSK525762
Sensitive: D – Preclinical
MYC amplification
Triple Negative Breast Cancer
YPN005
Sensitive: D – Preclinical
MYC amplification
HCC
YPN005
Sensitive: D – Preclinical
MYC amplification
Estrogen Receptor Positive Breast Cancer
YPN005
Sensitive: D – Preclinical
MYC amplification
Pancreatic Cancer
YPN005
Sensitive: D – Preclinical
MYC amplification
Prostate Cancer
YPN005
Sensitive: D – Preclinical
MYC amplification
Small Cell Lung Cancer
YPN005
Sensitive: D – Preclinical
MYC amplification
Ovarian Cancer
YPN005
Sensitive: D – Preclinical
MYC amplification
Small Cell Lung Cancer
LY2606368
Sensitive: D – Preclinical
MYC amplification
Medulloblastoma
PCM-075
Sensitive: D – Preclinical